212 related articles for article (PubMed ID: 23667174)
1. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing.
Zeng Y; Wodzenski D; Gao D; Shiraishi T; Terada N; Li Y; Vander Griend DJ; Luo J; Kong C; Getzenberg RH; Kulkarni P
Cancer Res; 2013 Jul; 73(13):4123-33. PubMed ID: 23667174
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.
Abetamann V; Kern HF; Elsässer HP
Clin Cancer Res; 1996 Sep; 2(9):1607-18. PubMed ID: 9816340
[TBL] [Abstract][Full Text] [Related]
3. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
5. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells.
Welsh CF; Zhu D; Bourguignon LY
J Cell Physiol; 1995 Sep; 164(3):605-12. PubMed ID: 7544357
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
Fichtner I; Dehmel A; Naundorf H; Finke LH
Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216
[TBL] [Abstract][Full Text] [Related]
7. CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells.
Zhang P; Fu C; Bai H; Song E; Dong C; Song Y
FEBS Lett; 2014 Dec; 588(24):4573-82. PubMed ID: 25447529
[TBL] [Abstract][Full Text] [Related]
8. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells.
Lau WM; Teng E; Chong HS; Lopez KA; Tay AY; Salto-Tellez M; Shabbir A; So JB; Chan SL
Cancer Res; 2014 May; 74(9):2630-41. PubMed ID: 24618343
[TBL] [Abstract][Full Text] [Related]
9. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression.
Iczkowski KA; Omara-Opyene AL; Shah GV
Anticancer Res; 2006; 26(4B):2863-72. PubMed ID: 16886606
[TBL] [Abstract][Full Text] [Related]
10. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.
Reeder JA; Gotley DC; Walsh MD; Fawcett J; Antalis TM
Cancer Res; 1998 Aug; 58(16):3719-26. PubMed ID: 9721884
[TBL] [Abstract][Full Text] [Related]
11. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level.
Iczkowski KA; Bai S; Pantazis CG
Anticancer Res; 2003; 23(4):3129-40. PubMed ID: 12926045
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesis.
Iida N; Bourguignon LY
J Cell Physiol; 1997 May; 171(2):152-60. PubMed ID: 9130462
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production.
Hiraga T; Ito S; Nakamura H
Cancer Res; 2013 Jul; 73(13):4112-22. PubMed ID: 23633482
[TBL] [Abstract][Full Text] [Related]
15. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns.
Miyake H; Hara I; Kamidono S; Eto H
J Urol; 2004 Sep; 172(3):1127-9. PubMed ID: 15311055
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression.
Hayes GM; Dougherty ST; Davis PD; Dougherty GJ
Cancer Gene Ther; 2004 Dec; 11(12):797-807. PubMed ID: 15359288
[TBL] [Abstract][Full Text] [Related]
17. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
Narla G; DiFeo A; Yao S; Banno A; Hod E; Reeves HL; Qiao RF; Camacho-Vanegas O; Levine A; Kirschenbaum A; Chan AM; Friedman SL; Martignetti JA
Cancer Res; 2005 Jul; 65(13):5761-8. PubMed ID: 15994951
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.
Hsieh IS; Chang KC; Tsai YT; Ke JY; Lu PJ; Lee KH; Yeh SD; Hong TM; Chen YL
Carcinogenesis; 2013 Mar; 34(3):530-8. PubMed ID: 23188675
[TBL] [Abstract][Full Text] [Related]
19. CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation.
Zhang P; Feng S; Liu G; Wang H; Fu A; Zhu H; Ren Q; Wang B; Xu X; Bai H; Dong C
Oncogene; 2016 Sep; 35(38):5056-5069. PubMed ID: 27041584
[TBL] [Abstract][Full Text] [Related]
20. Regulation of alternative splicing of CD44 in cancer.
Prochazka L; Tesarik R; Turanek J
Cell Signal; 2014 Oct; 26(10):2234-9. PubMed ID: 25025570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
